CoChat

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

PURPOSE: This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal cancer. METHODS: The first stage of this study was a standard "3 + 3" open-label dose-escalation scheme. Cohorts of 3-6 subjects were started with 120 mg of regorafenib given PO daily for 3 weeks of a 4 week cycle, plus 4.5 mg/kg of PF-03446962 given IV every 2 weeks. Doses of both drugs were adjusted according to dose-limiting toxicities (DLT). Plasma was collected for multiplexed ELISA analysis of factors related to tumor growth and angiogenesis. RESULTS: Seventeen subjects were enrolled, of whom 11 were deemed evaluable. Seven subjects were enrolled at dose level 1, and four were enrolled at level - 1. Overall, three DLTs were observed during the dose-escalation phase: two in level 1 and one in level - 1. A planned dose-expansion cohort was not started due to early termination of the clinical trial. Common adverse events were infusion-related reaction, fatigue, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dehydration, nausea, back pain, anorexia, and diarrhea. One subject achieved stable disease for 5.5 months, but discontinued treatment due to adverse events. CONCLUSIONS: The regimen of regorafenib and PF-03446962 was associated with unacceptable toxicity and did not demonstrate notable clinical activity in patients with refractory metastatic colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00280-019-03916-0

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Progression-free survival (a) and overall survival (b) for patients treated with PF-03446962 and regorafenib
Fig. 1 Progression-free survival (a) and overall survival (b) for patients treated with PF-03446962 and regorafenibCC BY · PubMed Central
Fig. 2 Biomarker change in response to Regorafenib and PF-03446962. a Early changes during cycle 1 of therapy and b late changes during cycle 2 of therapy
Fig. 2 Biomarker change in response to Regorafenib and PF-03446962. a Early changes during cycle 1 of therapy and b late changes during cycle 2 of therapyCC BY · PubMed Central
Fig. 3 Baseline expression of TGF-β related markers in patients with stable disease (SD, gold dot) progressive disease (PD, black dot)
Fig. 3 Baseline expression of TGF-β related markers in patients with stable disease (SD, gold dot) progressive disease (PD, black dot)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 21

Metadata

Authors
Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., Niedzwiecki, D., Watson, H., Bolch, E., Arrowood, C., Liu, Y., Nixon, A. B., & Hurwitz, H. I.
Affiliations
  • Duke University (US)
  • Duke Medical Center (US)
  • Genentech (US)
Corresponding author
Clarke, Jeffrey Melson
Venue
Cancer Chemotherapy and Pharmacology
Published
2019-08-23
Volume
84
Issue
4
Pages
909-917
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2969718979
Cited by
18
References
20
Citations by year
2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 6
FWCI
1.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Pfizer (WI178914)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
regorafenib, metastatic colorectal cancer, combination therapy, dose-limiting toxicity, maximum tolerated dose, angiogenesis, tumor growth factors, drug safety and tolerability
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Neoplasm Staging, Phenylurea Compounds, Pyridines, Colorectal Neoplasms, Drug Monitoring, Maximum Tolerated Dose, Activin Receptors, Type II, Early Termination of Clinical Trials, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). https://app.cochat.ai/papers/10.1007/s00280-019-03916-0
The paper
Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., Niedzwiecki, D., Watson, H., Bolch, E., Arrowood, C., Liu, Y., Nixon, A. B., & Hurwitz, H. I. (2019). A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-019-03916-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.